imaging as a non-invasive tool for visualizing tumor cell proliferation [1] . Since then, the technology has attracted substantial attention for its various applications in oncology. The principal mechanism in [ 18 F]FLT-PET imaging [2] is the uptake of the tracer by proliferating cells in the pyrimidine salvage pathway, mostly during S-phase. The tracer is then phosphorylated by thymidine kinase 1 (TK1), at which point it becomes trapped in the cells. As a pyrimidine analog, FLT primarily relies on the pyrimidine transporters, including equilibrative nucleoside transporters 1 and 2 (ENT1 and 2) and concentrative nucleoside transporters 1 and 3 (CNT1 and 3), to enter cells prior to being phosphorylated [3] [4] . Using a cell-based assay, FLT retention in cells was found to be strongly associated with TK1 expression [5] . In some cases, tumor cells predominately Author Manuscript Published OnlineFirst on December 14, 2011; DOI: 10.1158/1078-0432. CCR-11-1433 synthesize the nucleosides that are needed for cell growth de novo [6] , which results in low [ Because antiproliferation is often a primary or secondary phenotypic change caused by cytotoxic and targeted therapy, [
18 F]FLT-PET imaging seemed to be a comparatively straight-forward approach for tracking therapeutic-associated cell cycle arrest before morphological changes become measurable [10] . In comparison, the conventional biopsy approach used in proof of mechanism studies is generally invasive and often shows histopathological heterogeneity. In this respect, translational imaging research has been considerably emphasized for correlating [ A number of preclinical [ imaging led to early detection of a therapeutic response to the EGFR inhibitor gefitinib in advanced lung adenocarcinoma [15] . The robust inhibition of CDK4/6 enzymatic activity by PD-0332991 [16] resulted in a significant decrease in [ In an attempt to find an alternative tool for measuring the uptake of an FLT tracer in tumors, Wenlin Li and colleagues [18] 
Materials and Methods
PD 0332991 was synthesized by chemists at Pfizer [16] . Unless otherwise noted, all cell lines and fine chemicals were purchased from ATCC (Rockville) and Sigma-Aldrich, respectively. MDA-MB-231Luc was purchased from Xenogen (Caliper Company).
MDA-MB-231R was established by continuous exposure of MDA-MB-231 cells to Taxol (20 nM). The antibodies used were anti-Ki67 (Lab Vision), anti-BrdU (BD Pharmingen), anti-Human TK 1 (Abcam) and anti-phospho-Rb (Ser780, Santa Cruz).
In vitro assays
Cell cycle analysis was performed with a FACS Calibur system (Becton-Dickinson) using the CycleTEST Plus kit (Becton-Dickinson). The mRNA expression levels of the nucleoside transporters was assessed by using the RNeasy kit (Qiagen) on an ABI Prism 7900 (Applied Biosystems). The mRNA expression levels of the nucleotide transporters was assessed by reverse-transcription PCR (RT-PCR) using ABI Prism 7900 (Applied Biosystems). Total RNA was isolated using RNeasy kit (Qiagen). The RNA concentration and quality was assessed using nanoDrop (Thermo-Scientific) and 2100
Bioanalyzer (Agilent), respectively. The cDNA was synthesized using cDNA high capacity RT kit (Applied Biosystems) and amplified real time using Taqman assays for human CNT1-3 and ENT1-4 (Applied Biosystems). The expression levels was normalized to endogenous GAPDH. For the in vitro FLT uptake test, tumor cells in the , such that the mean value of tumor size was identical between the groups. Vehicle or PD 0332991 (150 mg/kg) was p.o. administered to mice once daily for 14 days. Tumor growth inhibition (TGI) [21] was calculated after treatment was ended. scanner (Siemens Medical Solutions) and a GE eXplore microCT scanner (GE Healthcare), respectively, as described previously [21] . Tumor-bearing mice were anesthetized and administered 250 µCi (1 -2 µg/kg) of [ After 60-80 min, PET imaging was initiated, followed by a subsequent CT scan (5 min) for anatomical reference. The imaging process was finished within 2 hr of the tracer injection. Reconstructed PET and CT data were co-registered and volumes of interest (VOIs) were hand-drawn to fit the primary tumor according to the CT and PET data sets.
The standardized uptake value (SUV) was calculated using the following formula:
where C PET is the measured activity in the volume of interest, ID is the injected dose (µCi) and W is the mouse body weight. In this report, [ 
Results

Variable [
F]FLT tracer uptake in xenograft models
To utilize [ 
The correlation of tumor growth and histological markers of proliferation in xenograft models
Histological analyses of multiple proliferation markers, including BrdU, Ki67 and TK1, were performed in xenografts that were in the exponential growth stage. Among these markers, BrdU uptake and Ki67 are two established measures of proliferation. Tumorbearing mice were i.p. administered BrdU (50 mg/kg). Tumors were harvested after 2 hr.
Quantitative histological analysis of IHC positivity was performed using the CRI imaging Given that Ki67 is also expressed during other non-S phases, with the exception of G0, we expected that the fraction of Ki67-positive cells does not necessarily reflect the cell proliferation state of these tumor models. A distinctive feature of theTK1 staining was that in addition to the tumor cell cytoplasm, the interstitial space was positive for TK1, which might be due to the constitutive release of thymidine kinase by the dead or dying tumor cells [24] [25] . BrdU, respectively. Because both assays were performed at 2 hr post tracer injection, the tracer exposure was assessed for the AUC 0-2 hr value.
FLT plasma exposure was assessed at 2 µg/kg, an estimated dose level used in preclinical [ 18 F]FLT-PET imaging. The mean plasma AUC 0-2 hr value was 2 ng*hr/ml ( Figure 4A ), which was markedly (~200 fold) lower than the intrinsic plasma thymidine exposure in either naïve or tumor-bearing mice (AUC 0-2 hr = 400 ng*hr/ml). In contrast, BrdU at the 50 mg/kg dose level yielded an AUC 0-2 hr of 1800 ng*hr/ml, which was more than 4-fold higher than the thymidine AUC 0-2 hr.
In healthy human volunteers and cancer patients, plasma thymidine concentrations have been reported to be 320-fold lower than in rodents [27] . We obtained similar results when analyzing the thymidine plasma levels from 10 healthy human volunteers. The mean AUC 0-2 hr value for healthy volunteers was approximately 4.4 ng*hr/ml (Thd = 2.5 ng/ml), whereas the estimated plasma AUC 0-2 hr value for FLT was significantly lower (0.028 ng*hr/ml) during [ 
Intrinsic tumor thymidine level negatively regulates FLT uptake
The intrinsic thymidine level in tumors was further assessed in order to correlate it with FLT tracer avidity in the tested models. Naïve plasma and tumors (200 -600mm 3 ) were collected to assess thymidine level using LC/MS analysis. These tumor models exhbited variable levels of thymidine, despite having comparable plasma levels across all models In the follow-up study, tumor-bearing mice were administered multiple doses of thymidine via the mini-pumps. Four hours after pump implantation, when plasma thymidine levels reached a steady-state, FLT (2 µg/kg) was i.p. administered. Two hours after the injection of FLT, plasma and tumors were collected for pharmacokinetic analysis. As illustrated in Figure 4C , when the thymidine levels in the plasma and tumors increased, the tumor FLT-MP levels decreased accordingly. In a separate cohort of tumor-bearing mice, the anti-proliferative activity of PD-0332991 was further evaluated using [ 
Discussion
We examined whether [ 
not shown). Coupled with this finding, it was also suggested that FLT delivery can potentially be affected by other factors, such as changes in vascular permeability and perfusion after treatment [9] . Since it is uncommon to consider background normalization for data analysis in the clinical setting, the exposure and biodistribution of FLT, as an exogenously injected tracer, could be a contributing factor that leads to false readout for [ 
The biological relevance of this study was shown by the modulation of phospho-Rb 
